| 116 |
decreased |
calcium-transporting ATPase activity
(GO:0005388)
|
calcium ion-transporting ATPase complex
(GO:0090534)
|
51: Inhibition, Ca++ ATPase
|
| 115 |
decreased |
|
Follicle stimulating hormone
(CHEBI:81569)
|
129: Reduction, Gonadotropins, circulating concentrations
|
| 114 |
decreased |
|
Luteinizing hormone
(CHEBI:81568)
|
2 Events
|
| 113 |
decreased |
oocyte development
(GO:0048599)
|
|
309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
|
| 112 |
decreased |
oocyte growth
(GO:0001555)
|
|
309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
|
| 111 |
decreased |
receptor-mediated endocytosis
(GO:0006898)
|
vitellogenins
(MESH:D014819)
|
309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
|
| 110 |
decreased |
|
vitellogenins
(MESH:D014819)
|
221: Reduction, Plasma vitellogenin concentrations
|
| 109 |
decreased |
egg quantity
(VT:1000294)
|
|
2 Events
|
| 108 |
decreased |
gene expression
(GO:0010467)
|
vitellogenins
(MESH:D014819)
|
285: Reduction, Vitellogenin synthesis in liver
|
| 107 |
increased |
androgen receptor activity
(GO:0004882)
|
androgen receptor
(PR:000004191)
|
25: Agonism, Androgen receptor
|
| 106 |
increased |
gene expression
(GO:0010467)
|
prostaglandin G/H synthase 2
(PR:000013428)
|
1269: Increase, COX-2 expression
|
| 105 |
morphological change |
abnormal cardiovascular system physiology
(MP:0001544)
|
|
317: Altered, Cardiovascular development/function
|
| 104 |
morphological change |
developmental process
(GO:0032502)
|
cardiovascular system
(UBERON:0004535)
|
None
|
| 103 |
disrupted |
protein dimerization activity
(GO:0046983)
|
aryl hydrocarbon receptor nuclear translocator
(PR:000004303)
|
None
|
| 102 |
disrupted |
protein dimerization activity
(GO:0046983)
|
aryl hydrocarbon receptor
(PR:000003858)
|
None
|
| 101 |
increased |
aryl hydrocarbon receptor activity
(GO:0004874)
|
aryl hydrocarbon receptor
(PR:000003858)
|
18: Activation, AhR
|
| 100 |
decreased |
|
fertility
(MESH:D005298)
|
6 Events
|
| 99 |
decreased |
regulation of gene expression
(GO:0010468)
|
androgen receptor
(PR:000004191)
|
286: Altered, Transcription of genes by the androgen receptor
|
| 98 |
arrested |
developmental process
(GO:0032502)
|
male reproductive organ
(UBERON:0003135)
|
240: Feminisation or incomplete development, Primary and accessory male sex organs
|
| 97 |
abnormal |
Wnt signaling pathway
(GO:0016055)
|
Wnt signalosome
(GO:1990909)
|
310: Alteration, Wnt pathway
|
| 96 |
decreased |
androgen receptor activity
(GO:0004882)
|
androgen receptor
(PR:000004191)
|
2 Events
|
| 95 |
morphological change |
|
male reproductive organ
(UBERON:0003135)
|
348: Malformation, Male reproductive tract
|
| 94 |
decreased |
|
testosterone
(CHEBI:17347)
|
2 Events
|
| 93 |
decreased |
testosterone biosynthetic process
(GO:0061370)
|
testosterone
(CHEBI:17347)
|
5 Events
|
| 92 |
decreased |
mitochondrial transport
(GO:0006839)
|
cholesterol
(CHEBI:16113)
|
447: Reduction, Cholesterol transport in mitochondria
|